대한뉴팜

Daehan Nupharm is expanding the supply of its antivenom product and varicella (chickenpox) vaccine. In November last year, the company signed an agreement with Boran Pharma to launch Korea’s only treatment for pit viper bites, the antivenom injection. In December, it began sales of the country’s first introduced varicella vaccine, and starting this month, it has begun offering the Japanese encephalitis live vaccine.

The Boran Dried Pit Viper Antivenom Injection is the only snake venom antidote available in Korea. Upon injection, it rapidly neutralizes venom toxins through antigen-antibody binding, significantly reducing venom concentration within one hour of administration. Particularly, about 44% of snakebite cases reported in autumn are severe. To address this, Daehan Nupharm supplies antivenom to emergency medical institutions to enable prompt treatment of life-threatening acute intoxication.

The Variel Vaccine is Korea’s first varicella vaccine and an attenuated live vaccine based on the Oka strain, which represents the most common genotype of varicella-zoster virus (VZV). As one of the National Immunization Program (NIP) vaccines, it is the only varicella vaccine in Korea that can be administered to adolescents and adults as well as children, with no age restrictions.

The CDJEVAX Japanese Encephalitis Live Vaccine, launching this month, is the only live vaccine included in the National Immunization Program. Approved in 1989, it has been administered to over 200 million people worldwide over a ten-year period. It was the first vaccine for children to receive WHO Prequalification (PQ) and has demonstrated safety through studies involving more than one million children, showing minimal adverse reactions. With a two-dose regimen providing over 95% preventive efficacy, it offers greater dosing convenience compared to vaccines requiring five doses.

This year, Daehan Nupharm aims to expand distribution of these three products and stabilize their market presence, with a goal of achieving combined sales exceeding KRW 5 billion by 2027. The company also plans to strengthen partnerships and advance joint research and development initiatives to ensure sustainable growth.